Summary In previous studies we have shown down-regulation of class I major histocompatibility complex (MHC) expression in a significant proportion of primary cervical carcinomas, which was found to be strongly correlated with loss of expression of the transporter associated with antigen presentation (TAP). By contrast, class II MHC expression was frequently up-regulated on neoplastic keratinocytes in these malignancies. In order to investigate whether these changes are associated with biological behaviour of the tumours, 20 cervical carcinomas were analysed for MHC (HLA-A, HLA-B/C, HLA-DR) and TAP-1 expression in the primary tumours and in lymph node metastases by immunohistochemistry. The results showed a significant increase in the prevalence of HLA-A and HLA-B/C down-regulation in metastasised neoplastic cells as compared with the primary tumour (P = 0.01). In all cases this was accompanied by loss of TAP-I expression. Up-regulated HLA-DR expression was found exclusively in primary tumours and was absent in the corresponding metastases (P= 0.002). These data are consistent with the hypothesis that loss of TAP-1 and the consequent down-regulation of class I MHC expression provides a selective advantage for neoplastic cervical cells during metastasis. Furthermore, the lack of class II MHC expression in metastasised cells either reflects a different local lymphokine production or indicates that these cells may have escaped CD4+ cytotoxic T-lymphocyte (CTL)-mediated killing.
Recognition of antigen by the cellular immune system is dependent on the function of major histocompatibility complex (MHC) cell-surface molecules, encoded by the HLA genes in human. Class I MHC molecules preferably present endogenous proteins to CD8+ cytotoxic T lymphocytes (CTLs) as small antigenic peptides (Townsend et al., 1985) . These peptides are generated by degradation of proteins in the cytosol, possibly involving the proteasome complex (Goldberg & Rock, 1992) . Subsequently peptides are translocated into the endoplasmic reticulum (ER) by the transporter associated with antigen presentation (TAP) (Trowsdale et al., 1990; Spies et al., 1990; Neefjes et al., 1993; Shepherd et al., 1993) . The population of class I MHC molecules with allelic variation in the vicinity of the antigenbinding cleft allows a wide variety of peptide sequences to bind to class I MHC in the ER (Falk et al., 1990) , resulting in their presentation at the cell surface. The MHC-antigenic peptide complex can then activate specific CTLs to proliferate, and these will eventually destroy the antigenpresenting cell (Townsend et al., 1985) . Down-regulation of class I MHC expression has frequently been reported in human malignancies . Such down-regulation would supply a selective growth advantage for malignant tumours by allowing neoplastic cells to escape CTL-mediated destruction. Indeed when class I MHC expression is lost in breast (Concha et al., 1991) or laryngeal (Esteban et al., 1989) carcinomas, a significantly poorer clinical outcome is found.
Expansion of an antigen-specific CTL population in vivo mostly depends on interleukin 2 (IL-2) production by activated T-helper (Th) cells . This activation is mediated by recognition of opsonised exogenous or endogenous antigen in the context of class II MHC molecules, expressed on professional antigen-presenting cells (APCs) . In addition, class II MHC expression can be up-regulated on non-professional APCs, as has been observed in a variety of human malignancies (Sakai et al., 1987; van den Ingh et al., 1987; Paterson et al., 1988) . Such up-regulated class II MHC expression has been reported to have a positive (Esteban et al., 1990) or negative (Ruiter et al., 1986) effect with regard to prognosis.
Changes in both class I and II MHC expression have been found in a substantial number of premalignant and malignant lesions of the uterine cervix, containing human papillomavirus (HPV) genotypes (Connor & Stern, 1990; Glew et al., 1992 Glew et al., , 1993 Cromme et al., 1993a) . Down-regulation of class I MHC expression in cervical carcinomas is apparently post-transcriptionally controlled (Cromme et al., 1993b) . This is consistent with the observation that class I MHC loss is frequently associated with a failure to detect one of the subunits of the transporter associated with antigen presentation (TAP-1) (Cromme et al., 1993c (Cromme et al., 1993a) , employing a general primer (GP5/6), type-specific primer-mediated PCR strategy (Snijders et al., 1990; van den Brule et al., 1990; Walboomers et al., 1992 analysed by PCR using human P-globin gene-specific primers.
Liver sections, cut between carcinoma samples, were analysed by PCR to check for contamination during tissue processing and were consistently negative for HPV, while the ,-globin primer set gave a positive PCR result.
Immunohistochemistry
Immunohistochemical staining was performed as previously described (Cromme et al., 1993a) . Briefly, sections adhered to coated [0.1% (w/v) poly-L-lysine) slides were deparaffinised with xylene, rehydrated and endogenous peroxidase was blocked by incubating for 30 min with methanol, containing 0.3% (v/v) hydrogen peroxide. After rinsing in phosphatebuffered saline, pH 7.4 (PBS), sections of each biopsy were processed according to the appropriate protocol for the different primary antibodies (Table I) .
After pretreatment and washing repeatedly in PBS, sections were preincubated with normal goat (1:20) or horse (1:50) serum, depending on the secondary antibodies used, for 15min and then incubated with primary antibodies (Table I) .
Bound murine antibodies were detected with a biotinylated horse anti-mouse Ab, 1:500 (Vector Lab., Burlingame, CA, USA), bound rabbit antibodies with a biotinylated goat antirabbit Ab, 1:500 (Vector Lab.). Detection of binding of secondary antibody was performed using horseradish peroxidase coupled to avidin-biotin complex, 1:500 (Vector Elite, Vector Lab.), after which the complex was visualised using diaminobenzidine and hydrogen peroxide. Slides were counterstained with haematoxylin, dehydrated and mounted in Depex. (Table II) . Presence and typing of HPV in the metastasised neoplastic cells in the lymph node was also analysed. No differences were found in HPV types between the primary tumours and lymph nodes.
Class I MHC and TAP-I expression in primary tumours After ascertaining general epitope conservation and the epithelial nature of the neoplastic cells with a keratin-specific antibody, immunohistochemical staining for class I MHC expression was analysed with antibodies specific for HLA-A (i.e. HC-A2) and HLA-B/C (i.e. HCIO) locus products.
All carcinomas showed similar staining patterns for HLA-A and HLA-B/C expression at the primary tumour site (Table II ). An example is given in Figure 1 , in which areas of neoplastic cells of carcinoma show lack of staining for both HLA-A (Figure la) and HLA-B/C (Figure lb) , whereas immune cells in the stroma and within the neoplastic area are labelled for both antigens.
From the 20 primary tumours analysed, four were scored as negative for HLA-A and HLA-B/C, i.e. virtually all neoplastic cells show loss of staining. An additional seven were judged as heterogeneous, i.e. positive tumour areas adjacent to negative ones. The remaining nine carcinomas were scored as positive, i.e. the vast majority of neoplastic cells showing membranous staining.
Expression of one of the subunits of the transporter associated with antigen presentation (TAP-1) was analysed with a polyclonal serum, specific for the TAP-1 protein (Cromme et al., 1993c) . As shown in Figure lc , loss of staining for TAP-1 was found in those neoplastic areas of primary tumours that lacked staining for HLA-A and HLA-B/C locus products. This congruency was invariably found in all primary tumours (Table II) , which is in accordance with previous findings (Cromme et al., 1993c) .
Class I MHC and TAP-i expression in lymph node metastases In the lymph nodes the same congruency between class I MHC and TAP-1 expression was found (Table II) . Metastasised neoplastic cells of carcinoma 76-1849 show loss of HLA-B/C expression ( Figure 2b ) and staining for TAP-1 (Figure 2c) . The same area is negative for HLA-A expression as well (not shown).
However, the frequency of class I MHC and TAP-1 downregulation was higher in the metastasised neoplastic cells in the lymph nodes than in their primary tumours. An increase in down-regulation of class I MHC expression was found in 12 patients when comparing primary tumours and metastases, as indicated in the MHC-I trend column of Table II. An example is given in Figure 2 , in which carcinomas 76-1849 shows positive membranous staining for HLA-B/C at the primary tumour site (Figure 2a) , while metastasised cells are clearly negative for HLA-B/C (Figure 2b ). In the remaining eight patients the expression patterns in primary tumours and metastases were similar. Two lesions exhibited weak cytoplasmic staining for HLA-A locus products in some (Table II were taken together and scored as down-regulated. Such down-regulation was observed in 18 out of 20 metastases, compared with 11 out of 20 primary tumours. This difference is statistically significant by chi-square test (P-value 0.01).
Class II MHC expression in primary tumours Class II MHC expression was analysed by immunohistochemistry with an antibody recognising HLA-DR locus products (i.e. LN3). Activated T cells, B cells and macrophages served as internal positive controls, whereas normal squamous epithelium present in the same section was never stained. When a substantial number of neoplastic areas, i.e. 25% or more of the neoplastic cells in a section, stain for HLA-DR, lesions were classified as positive (+). As shown for carcinoma 72-5453 in Figure 3a , neoplastic cells clearly stain positive for HLA-DR at the cell membrane, in addition to positive staining of immune cells in the stroma. In total, nine out of 20 primary tumours were scored as positive for HLA-DR (Table II) . Class II MHC expression in lymph node metastases No HLA-DR expression was observed on neoplastic epithelial cells in the lymph nodes, while lymphocytes in the nodes stained positive. Corresponding tumours at the primary site were scored as positive in nine cases, and an example of this differential staining is shown in Figure 3 . Lack of staining for HLA-DR of metastasised neoplastic cells was observed (Figure 3b ), while the same patient exhibits up-regulated HLA-DR expression in the primary tumour (Figure 3a) . The difference in frequency of HLA-DR expression between primary tumours and metastases is statistically highly significant (P-value 0.002).
Discussion
Certain human papillomavirus (HPV) types are considered to play an important role in cervical carcinogenesis (Zur Hausen, 1989) . The major transformation protein E7 from high-risk HPV types (i.e. HPV 16 and 18) interferes with cell cycle control by complexing with the retinoblastoma tumoursuppressor protein (PRb) (Munger et al., 1989) , and the E7 open reading frame is consistently transcribed in HPVcontaining neoplastic cervical cells (Broker et al., 1989; van den Brule et al., 1991) . This viral protein has been shown to be immunogenic in vitro (Chen et al., 1991) , and immunisation with HPV 16-E7-derived peptide resulted in a protective CTL response in mice (Feltkamp et al., 1993) . Therefore the loss of class I MHC surface expression observed in HPVpositive neoplastic cervical cells (Connor & Stern, 1990; Cromme et al., 1993a) (Sillman & Sedlis, 1987) and the significantly shorter disease-free survival of HIV-seropositive cervical cancer patients (Maiman et al., 1993) .
The dominant role for the adaptive immune response in controlling metastasis is further supported by the frequent loss of class I MHC expression in vivo during lymph node metastasis in breast, colon, urinary and kidney carcinomas (Cordon-Cardo et al., 1991) and in melanomas (Lopez-Nevot et al., 1986; Ruiter et al., 1986) . On the other hand, several reports have shown that an increase in expression of class I MHC results in a higher number of metastases in mice (De Baetselier et al., 1980; Katzav et al., 1984; Algarra et al., 1991) . This could be due to a decreased natural killer (NK)-cell susceptibility of class I MHC-positive cells, according to the hypothesis that NK cells recognise 'missing self (Karre et al., 1986) . However, restoration of class I MHC expression by y-interferon treatment of melanoma cells reduces their metastatic potential (Zoller et al., 1988) , indicating that the increased efficacy of T-cell response can overcome the loss of a non-adaptive immune defence in vitro.
Recently we have shown that the down-regulation of class I MHC expression is strongly associated with loss of the transporter associated with antigen presentation (TAP) in primary cervical carcinomas (Cromme et al., 1993c) . This fits into the model of post-transcriptional regulation of class I MHC expression (Cromme et al., 1993b) , in which lack of class I MHC stabilisation in the ER occurs when peptide levels are reduced owing to loss of TAP. The observation in this study that the increased frequency of class I MHC down-regulation in lymph node metastases is consistently accompanied by loss of TAP-1 protein confirms and extends the relationship between the expression of HLA and TAP-1 and indicates a role during tumorigenesis in vivo. The regulation of TAP-1 documented in this and other studies (Cromme et al., 1993c; Restifo et al., 1993) may not therefore be epiphenomenon but a target for selection during progression of malignant disease. Further investigation into the mechanisms of TAP-1 down-regulation could provide the tool to restore antigen presentation and consequently render neoplastic cells sensitive to CD8+ CTL-mediated immune therapy.
Two patients in this study showed no down-regulation of class I MHC expression in either the primary tumour site or the lymph node, but were HLA-DR positive in the primary tumour. Presumably other mechanisms of immune escape can operate in these cases. Under some circumstances upregulated class II MHC expression on keratinocytes can result in T-cell anergy or tolerance, presumably due to an incorrect antigen presentation (Gaspari et al., 1988; Bal et al., 1990) . Therefore de novo HLA-DR expression on neoplastic epithelial cells as observed in this and other studies (Glew et al., 1992; Cromme et al., 1993a ) may have induced a state of T-cell anergy.
Alternatively, class II MHC molecules may serve as restriction elements for tumour-specific CD4+ CTLs. In line with this is the finding that peripheral CD4+ T cells in HPVseropositive donors can lyse autologous B cells after pulsing with HPV 16-E7-encoded peptides, presumably in a class II MHC-restricted fashion (Altmann et al., 1992) . Provided that endogenous HPV proteins can enter the class II secretory pathway in vivo, in analogy with cytosolic vaccinia proteins (Jaraquemada et al., 1990) , the up-regulated HLA-DR expression could result in specific lysis of cervical tumour cells by CD4+ T cells. This would explain selection for HLA-DRnegative tumour cells during metastasis.
However, it cannot be excluded that the difference in frequency of HLA-DR expression between primary tumours and lymph node metastases is related to differences in local cytokine production (i.e. y-interferon, tumour necrosis factor) and therefore needs to be considered as a bystander effect.
Further research into the nature of infiltrating immune cells and their state of activation is required to establish which immune cell population has been primed. This could further elucidate which target cell recognition structures are negatively selected for during cervical carcinogenesis.
